Endo Releases Data on the Perception and Measurement of Cellulite Severity at ASDS Meeting

Thursday, October 11, 2018 | Personnel/Company News , Product Launches and Updates , Research and Publications , American Society for Dermatologic Surgery


The new Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a reliable tool for evaluating cellulite severity of the buttocks and thighs and correlates well with the Patient Reported Photonumeric Cellulite Severity Scale, according to research presented by Endo International plc. at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Phoenix, AZ.

"It is important that healthcare providers and their patients have a reliable tool for evaluating cellulite severity,” says ," says Matthew Davis, M.D., R.Ph., Chief Medical Officer, Senior Vice President, Research and Development, Branded Pharmaceuticals of Endo Pharmaceuticals, in a news release. “We believe the 5-point photonumeric scales enable patients and the clinician treating their cellulite to be aligned during both the informed consent process prior to treatment, and post treatment when they are evaluating the outcomes.”

A second study found that the gender of a health care provider does not appear to impact assessment of cellulite severity ratings.

In the study, health care providers rated female cellulite severity by viewing a set of digital images that represented the range of cellulite severity on buttocks or thighs.

Endo is developing injectable collagenase clostridium histolyticum (CCH, XIAFLEX) for the treatment of cellulite. CCH is currently approved in the U.S. for adult Dupuytren’s contracture and Peyronie’s disease.

 

Next Story

Comments

You must be logged in to leave a comment.